dc.contributor.author |
Dodgen, Tyren Mark
|
|
dc.contributor.author |
Drögemöller, Britt I.
|
|
dc.contributor.author |
Wright, Galen E.B.
|
|
dc.contributor.author |
Warnich, Louise
|
|
dc.contributor.author |
Steffens, Francois E.
|
|
dc.contributor.author |
Cromarty, Allan Duncan
|
|
dc.contributor.author |
Alessandrini, Marco
|
|
dc.contributor.author |
Pepper, Michael Sean
|
|
dc.date.accessioned |
2015-10-30T07:50:55Z |
|
dc.date.issued |
2015-08 |
|
dc.description.abstract |
AIM : To align predicted and measured CYP2C19 phenotype in a South African cohort.
MATERIALS AND METHODS : Genotyping of CYP2C19*2, *3, *9, *15, *17, *27 and *28 was
performed using PCR-RFLP, and an Activity Score (AS) system was used to predict phenotype.True phenotype was measured using plasma concentrations of omeprazole and its metabolite
5’-hydroxyomperazole. RESULTS : Partial genotype-phenotype discrepancies were reported, and an
adapted AS system was developed, which showed a marked improvement in phenotype
prediction. Results highlight the need for a more comprehensive CYP2C19 genotyping approach
to improve prediction of omeprazole metabolism. CONCLUSION : Evidence for the utility of a
CYP2C19 AS system is provided, for which the accuracy can be further improved by means of
comprehensive genotyping and substrate specific modification. |
en_ZA |
dc.description.embargo |
2016-08-31 |
|
dc.description.librarian |
hb2015 |
en_ZA |
dc.description.sponsorship |
Departments of Pharmacology and Immunology, University of Pretoria; the National Research Foundation of South Africa (NRF) grant numbers FA2006032700005 and TK2006051500005; the National Health Laboratory Services of South Africa (NHLS); the South African Medical Research Council (SAMRC) Extramural Unit for Inflammation and Immunity, and Ampath Laboratories, South Africa. |
en_ZA |
dc.description.uri |
http://www.futuremedicine.com/loi/pgs |
en_ZA |
dc.identifier.citation |
Dodgen, TM, Drögemöller, BI, Wright, GEB, Warnich, L, Steffens, FE, Cromarty, AD, Alessandrini, M & Pepper, MS 2015, 'Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort', Pharmacogenomics, vol. 16, no. 12, pp. 1343-1354. |
en_ZA |
dc.identifier.issn |
1462-2416 (print) |
|
dc.identifier.issn |
1744-8042 (online) |
|
dc.identifier.other |
10.2217/pgs.15.80 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/50280 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Future Medicine |
en_ZA |
dc.rights |
Future Medicine |
en_ZA |
dc.subject |
CYP2C19 |
en_ZA |
dc.subject |
Oomeprazole |
en_ZA |
dc.subject |
Activity score system |
en_ZA |
dc.subject |
Genotype-phenotype correlation |
en_ZA |
dc.subject |
South Africa (SA) |
en_ZA |
dc.title |
Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort |
en_ZA |
dc.type |
Postprint Article |
en_ZA |